The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

This lengthy study with the drug Mounjaro seems to point to even better success than they’d hoped. Eli Lilly, the mind behind ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

WHAT TO KNOW ABOUT GLP-1 SHORTAGES — It’s been a busy week in the diabetes and weight-loss drug world as Eli Lilly renews its push to shut down the compounding of its tirzepatide products and the ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

GLP-1 drugs such as Wegovy and Ozempic (semaglutide) and Zepbound (tirzepatide) may offer benefits that extend beyond aiding ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.